Table 1 Patients’ background characteristics
GA group | Control group | P value | |
|---|---|---|---|
(n = 34) | (n = 33) | ||
Age (years)a | 62.3 ± 12.7 | 59.8 ± 9.4 | 0.396 |
Sex, n (%) | |||
Male | 10 (29.4) | 8 (24.2) | 0.759 |
Female | 24 (70.6) | 25 (75.8) | |
BMI, kg/m2a | 22.6 ± 3.2 | 23.6 ± 2.5 | 0.189 |
ECOG PS, n (%) | |||
0 | 24 (70.6) | 24 (72.7) | 0.846 |
1 | 10 (29.4) | 9 (27.3) | |
Tumor type, n (%) | |||
Colorectal cancer | 17 (50.0) | 17 (51.5) | 0.589 |
Breast cancer | 17 (50.0) | 16 (48.5) | |
Tumor stage, n (%) | |||
II to III | 17 (50.0) | 15 (45.5) | 0.710 |
IV | 17 (50.0) | 18 (54.5) | |
Blood/biochemical testsa | |||
Total protein, g/dL | 6.50 ± 0.45 | 6.40 ± 0.45 | 0.434 |
Albumin, g/dL | 3.96 ± 0.37 | 3.84 ± 0.31 | 0.251 |
White blood cell count, × 103/μL White blood cell count, ×103/μL | 4.95 ± 1.48 | 5.33 ± 1.67 | 0.383 |
Neutrophil count, × 103/μL Neutrophil count, × 103/μL | 3.11 ± 1.28 | 3.21 ± 1.26 | 0.777 |
Hemoglobin, g/dL | 11.9 ± 1.37 | 11.9 ± 1.29 | 0.944 |
Serum creatinine, mg/dL | 0.66 ± 0.16 | 0.65 ± 0.20 | 0.931 |
Aspartate transaminase | 28.3 ± 23.1 | 27.1 ± 23.3 | 0.850 |
Alanine transaminase | 28.4 ± 25.7 | 26.3 ± 16.6 | 0.731 |
C-reactive protein | 0.48 ± 0.68 | 0.34 ± 0.49 | 0.406 |
Chemotherapy regimen, n (%) | |||
5-FU + l-LV + CPT-11 | 7 (20.6) | 8 (24.2) | 0.781 |
5-FU + l-LV + L-OHP | 10 (29.4) | 9 (27.3) | |
5-FU + EPI + CPA | 17 (50.0) | 16 (48.5) | |
Molecular targeted drug, n (%) | |||
Cetuximab | 1 (2.9) | 1 (3.0) | 0.551 |
Panitumumab | 4 (11.8) | 6 (18.2) | |
Bevacizumab | 10 (29.4) | 11 (33.3) | |
None | 19 (55.9) | 15 (45.5) | |
Mouthwash, n (%) | |||
Sodium azulene sulfonate | 1 (2.9) | 3 (9.1) | 0.356 |
Benzethonium chloride | 17 (50.0) | 16 (48.5) | 0.901 |
Concomitant drug, n (%) | |||
Polaprezinc | 18 (52.9) | 24 (72.7) | 0.094 |
Rebamipide | 2 (5.9) | 1 (4.5) | 1.000 |
Non-steroidal antipyretic analgesic | 6 (17.6) | 6 (27.3) | 0.508 |
Opioid analgesic | 7 (20.6) | 1 (4.5) | 0.130 |
Nutritional supplement, n (%) | 3 (8.8) | 1 (3.0) | 0.614 |
Numerical Rating Scale score before the trial | 6.12 ± 2.07 | 5.68 ± 1.32 | 0.385 |